The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Abstract
In Brief Purpose: To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin, Genentech Inc.) for the treatment of neovascular age-related macular degeneration (ARMD). Methods: A retrospective review was performed on consented patients with neovascular ARMD receiving intravitreal bevacizumab therapy. All patients received intravitreal bevacizumab at baseline with additional monthly injections given at the discretion of the treating physician. At each visit, a routine Snellen visual acuity assessment was performed followed by an ophthalmic examination and optical coherence tomography (OCT) imaging. Results: Fifty–three eyes of 50 patients received an intravitreal bevacizumab injection between May and August 2005. Including the month 3 visit, the average number of injections was 2.3 out of a maximum of 4 injections. No serious drug-related ocular or systemic adverse events were identified. Improvements in visual acuity and central retinal thickness measurements were evident by week 1 and continued through month 3. At month 3, the mean visual acuity improved from 20/160 to 20/125 (P<0.001) and the mean central retinal thickness decreased by 99.6 μm (P<0.001). Conclusion: Off-label intravitreal bevacizumab therapy for neovascular ARMD was well tolerated over 3 months with improvements in visual acuity and OCT central retinal thickness measurements. While the long-term safety and efficacy of intravitreal bevacizumab remain unknown, these short-term results suggest that intravitreal bevacizumab may be the most cost effective therapy for the treatment of neovascular ARMD. A retrospective review was performed on consecutively consented patients with neovascular ARMD receiving intravitreal bevacizumab therapy. While the long-term safety and efficacy of intravitreal bevacizumab remain unknown, the short-term results suggest that intravitreal bevacizumab may be the most cost effective therapy for the treatment of neovascular ARMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“6-line increase 2 (4) 2 (5) 3 (6) 3-line to 6-line increase 11 (22) 12 (29) 20 (38) 1-line to 3-line increase 12 (24) 9 (21) 8 (15) No change 20 (39) 13 (31) 14 (26) 1-line to 3-line decrease 4 (8) 3 (7) 4 (8) 3-line to 6-line decrease 2 (4) 3 (7) 3 (6) 6-line decrease 0 0 1 (2) 500 RETINA, THE JOURNAL OF RETINAL AND…”
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
Self-citationMICHELS, S., ROSENFELD, P., PULIAFITO, C., MARCUS, E., & VENKATRAMAN, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.007 · Cited by 664
Self-citationAdamis, A. P. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100130062010 · Cited by 635
SPAIDE, R. F., LAUD, K., FINE, H. F., KLANCNIK, J. M., MEYERLE, C. B., YANNUZZI, L. A., SORENSON, J., SLAKTER, J., FISHER, Y. L., & COONEY, M. J. (2006) · Retina · doi:10.1097/00006982-200604000-00001 · Cited by 630
Kvanta, A., Algvere, P., Berglin, L., & Seregard, S. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70522-7 · Cited by 620
Keyt, B. A., Berleau, L. T., Nguyen, H. V., Chen, H., Heinsohn, H., Vandlen, R., & Ferrara, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.13.7788 · Cited by 604
Bressler, N. M. (2001) · Cited by 599
Lopez, P. F., Sippy, B. D., Lambert, H. M., Thach, A. B., & Hinton, D. R. (1998) · Retina · doi:10.1097/00006982-199805000-00035 · Cited by 592
Increased expression of angiogenic growth factors in age-related maculopathy
Kliffen, M., Sharma, H. S., Mooy, C. M., Kerkvliet, S., & de Jong, P. T. V. M. (1997) · British Journal of Ophthalmology · doi:10.1136/bjo.81.2.154 · Cited by 502
Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H., & Ferrara, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5638 · Cited by 497
Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 448
FRANK, R. N., AMIN, R. H., ELIOTT, D., PUKLIN, J. E., & ABRAMS, G. W. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)72066-5 · Cited by 366
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Heier, J. S., Antoszyk, A. N., Pavan, P. R., Leff, S. R., Rosenfeld, P. J., Ciulla, T. A., Dreyer, R. F., Gentile, R. C., Sy, J. P., Hantsbarger, G., et al. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.052 · Cited by 360
Self-citationMordenti, J., Cuthbertson, R. A., Ferrara, N., Thomsen, K., Berleau, L., Licko, V., Allen, P. C., Valverde, C. R., Meng, Y. G., Fei, D. T. W., et al. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700507 · Cited by 350
THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR HEALTH AND DISEASE
ADAMIS, A. P., & SHIMA, D. T. (2005) · Retina · doi:10.1097/00006982-200502000-00001 · Cited by 334
Rakic, J.-M., Lambert, V., Devy, L., Luttun, A., Carmeliet, P., Claes, C., Nguyen, L., Foidart, J.-M., Noe¨l, A., & Munaut, C. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1092 · Cited by 321
ROSENFELD, P., SCHWARTZ, S., BLUMENKRANZ, M., MILLER, J., HALLER, J., REIMANN, J., GREENE, W., & SHAMS, N. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.01.043 · Cited by 223
Self-citationSystemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration
Moshfeghi, A. A., Rosenfeld, P. J., Puliafito, C. A., Michels, S., Marcus, E. N., Lenchus, J. D., & Venkatraman, A. S. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.070 · Cited by 205
Self-citationRosenfeld, P. J., Heier, J. S., Hantsbarger, G., & Shams, N. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.01.027 · Cited by 189
Self-citationOtani, A., Takagi, H., Oh, H., Koyama, S., Ogura, Y., Matumura, M., & Honda, Y. (2002) · Microvascular Research · doi:10.1006/mvre.2002.2407 · Cited by 128 · cited 1×
“6-line increase 2 (4) 2 (5) 3 (6) 3-line to 6-line increase 11 (22) 12 (29) 20 (38) 1-line to 3-line increase 12 (24) 9 (21) 8 (15) No change 20 (39) 13 (31) 14 (26) 1-line to 3-line decrease 4 (8) 3 (7) 4 (8) 3-line to 6-line decrease 2 (4) 3 (7) 3 (6) 6-line decrease 0 0 1 (2) 500 RETINA, THE JOURNAL OF RETINAL AND…”
Mordenti, J. J. (1999) · Toxicological Sciences · doi:10.1093/toxsci/52.1.101 · Cited by 78
Cited by
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 781
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
MICHELS, S., ROSENFELD, P., PULIAFITO, C., MARCUS, E., & VENKATRAMAN, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.007 · Cited by 664
Self-citationA survey of current trends in computational drug repositioning
Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv020 · Cited by 555
Metadata
- Authors
- RICH, R. M., ROSENFELD, P. J., PULIAFITO, C. A., DUBOVY, S. R., DAVIS, J. L., FLYNN, H. W., GONZALEZ, S., FEUER, W. J., LIN, R. C., LALWANI, G. A., NGUYEN, J. K., & KUMAR, G.
- Venue
- Retina
- Published
- 2006-05
- Volume
- 26
- Issue
- 5
- Pages
- 495-511
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1995708259
- Cited by
- 484
- References
- 28
- FWCI
- 66.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.